Oscotec Stock Fundamentals
| 039200 Stock | KRW 25,750 550.00 2.18% |
Oscotec fundamentals help investors to digest information that contributes to Oscotec's financial success or failures. It also enables traders to predict the movement of Oscotec Stock. The fundamental analysis module provides a way to measure Oscotec's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oscotec stock.
Oscotec |
Oscotec Company Current Valuation Analysis
Oscotec's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Oscotec Current Valuation | 996.59 B |
Most of Oscotec's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oscotec is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Oscotec has a Current Valuation of 996.59 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all Republic of Korea stocks is notably lower than that of the firm.
Oscotec Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Oscotec's current stock value. Our valuation model uses many indicators to compare Oscotec value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oscotec competition to find correlations between indicators driving Oscotec's intrinsic value. More Info.Oscotec is rated third in return on equity category among its peers. It also is rated third in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Oscotec by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Oscotec's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Oscotec Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oscotec's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oscotec could also be used in its relative valuation, which is a method of valuing Oscotec by comparing valuation metrics of similar companies.Oscotec is currently under evaluation in current valuation category among its peers.
Oscotec Fundamentals
| Return On Equity | -69.69 | |||
| Return On Asset | -0.15 | |||
| Profit Margin | (0.61) % | |||
| Operating Margin | (0.50) % | |||
| Current Valuation | 996.59 B | |||
| Shares Outstanding | 28.1 M | |||
| Shares Owned By Insiders | 16.37 % | |||
| Shares Owned By Institutions | 8.46 % | |||
| Price To Earning | 290.30 X | |||
| Price To Sales | 18.54 X | |||
| Revenue | 3.9 B | |||
| Gross Profit | 41.41 B | |||
| EBITDA | (13 B) | |||
| Net Income | (28.59 B) | |||
| Cash And Equivalents | 10.58 B | |||
| Cash Per Share | 748.14 X | |||
| Total Debt | 775.46 M | |||
| Debt To Equity | 0.20 % | |||
| Current Ratio | 1.37 X | |||
| Book Value Per Share | 1,092 X | |||
| Cash Flow From Operations | (8.76 B) | |||
| Target Price | 26788.0 | |||
| Number Of Employees | 17 | |||
| Beta | 0.82 | |||
| Market Capitalization | 590.14 B | |||
| Total Asset | 48.97 B | |||
| Retained Earnings | (22.53 B) | |||
| Working Capital | 11.85 B | |||
| Current Asset | 29.29 B | |||
| Current Liabilities | 17.44 B | |||
| Net Asset | 48.97 B |
About Oscotec Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oscotec's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oscotec using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oscotec based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Oscotec Inc. operates as a clinical stage drug discovery and development company. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea. OCT is traded on Korean Securities Dealers Automated Quotations in South Korea.
Other Information on Investing in Oscotec Stock
Oscotec financial ratios help investors to determine whether Oscotec Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oscotec with respect to the benefits of owning Oscotec security.